The past couple of weeks have been an ardent journey in researching the cause and effect of microbodies in our species. Apparently, it has been affecting the wild & big cats in the animal kingdom and we do not know how far can the deadly coronavirus show implications due to its mutation.
The recent study shows high level of proteins “suPAR” in the bloodstream of COVID-19 patient can predict the severity of the case.
suPAR – What is it?
The identity of protein, suPAR in the bloodstream might help the researchers to arrive at pinpoint analysis of the coronavirus stage. It may predict the severity of the COVID – 19 and the risks that follow.
The new study approach suggests that the protein soluble urokinase plasminogen activator receptor (suPAR) may is a vital roadmap for the prediction of the severity in the affected case.
The primary benefit: suPAR
This was published in a journal critical care where it would come of use to the clinical experts to segregate the severely affected cases to the ICU. Thus, making the best use of time and analytics under the circumstance.
Retaining the severely affected patients in the ICU and the rest of the least effect, who can manage at home.
Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.
Flattening the curve
The SARS-COV- 2 aka COVID – 19 has The sudden emergence and rapid spread of SARS-CoV-2, the virus that causes COVID-19, has put health services across the world at risk of being overwhelmed.
Patients who develop a severe infection of COVID-19 will often experience forms of respiratory failure, which, in turn, puts pressure on intensive care units (ICU).
Different governments have come to dilute the pressure to flatten the curve. Currently, we are falling short of ICU, when we are journey to the eye of the storm. The governments across the world are falling short of ICUs and medical essentials to support the overwhelming situation of the pandemic.
The last thing we could wish for is community transmission, this would ideally be the 3rd or 4th stage of the pandemic spread.
Educating the community:
Flattening the curve has predominantly occurred through social distancing measures. Scientists investigation has covered cases that are extremely severe but have no treatment options.
There is room for solutions coming during this first wave to predict and prevent disease severity. Managing the diseases can be attained to relieve pressure on hospitals and ICUs.
Is suPAR protein a predictor?
According to Prof. Jochen Reiser, the Ralph C. Brown, MD, Professor of Internal Medicine, Chairperson of the Department of Internal Medicine at Rush University, Chicago, and co-corresponding author of the study, “if we measure suPAR as part of diagnosing COVID-19, we may know whom to watch more and whom to send home.”
“Plasma suPAR levels give us a window into the course of the disease, allowing for an improved monitoring and applying new and supportive treatments early.”
– Prof. Jochen Reiser
- According to the study of data from the Rush University Medical Center and 57 patients from the University of Athens Medical School in Greece the evidence in the blood levels can proceed the reports.
- The researchers found that those with higher levels of suPAR in their bloodstream needed intubation more quickly than those with lower levels.
According to Prof. Reiser, “his is the first report in the world to show that suPAR is elevated in COVID-19 and is predictive.”
“Since suPAR is a reactant of the innate immune system, it’s an indicator of disease severity. These results show that the higher the plasma suPAR level, the worse the outcome will be in the lungs of these patients. The higher the suPAR level, the shorter the time before patients needed intubation.”
As Prof. Reiser notes, “there is a body of literature that suPAR is associated with poor outcomes from acute respiratory distress syndrome (a condition in many patients with severe COVID-19) and poor lung functioning in critically ill patients.”
- This study is only small, and so its findings require further research to confirm that suPAR is an effective predictor of COVID-19 severity. As noted in a recent article in the BMJ, this is a common issue for current published research on COVID-19 prediction models.
- The tracks will lead us in the right direction say researchers that leverages the fact, targeting suPAR is a treatment option or not.